CN105687177A - N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 - Google Patents

N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 Download PDF

Info

Publication number
CN105687177A
CN105687177A CN201610083044.4A CN201610083044A CN105687177A CN 105687177 A CN105687177 A CN 105687177A CN 201610083044 A CN201610083044 A CN 201610083044A CN 105687177 A CN105687177 A CN 105687177A
Authority
CN
China
Prior art keywords
dose
acetaminophen
maximum daily
daily dose
standard maximum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610083044.4A
Other languages
English (en)
Chinese (zh)
Inventor
莉奥诺.A.赫岑伯格
詹姆斯.安德勒斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105687177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN105687177A publication Critical patent/CN105687177A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201610083044.4A 2009-07-15 2010-07-15 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 Pending CN105687177A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22567909P 2009-07-15 2009-07-15
US61/225679 2009-07-15
CN2010800368102A CN102573463A (zh) 2009-07-15 2010-07-15 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800368102A Division CN102573463A (zh) 2009-07-15 2010-07-15 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法

Publications (1)

Publication Number Publication Date
CN105687177A true CN105687177A (zh) 2016-06-22

Family

ID=43449800

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610083044.4A Pending CN105687177A (zh) 2009-07-15 2010-07-15 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法
CN2010800368102A Pending CN102573463A (zh) 2009-07-15 2010-07-15 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800368102A Pending CN102573463A (zh) 2009-07-15 2010-07-15 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法

Country Status (6)

Country Link
US (1) US20110014285A1 (https=)
EP (1) EP2453743B1 (https=)
JP (2) JP2012533559A (https=)
CN (2) CN105687177A (https=)
CA (1) CA2767833C (https=)
WO (1) WO2011008976A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
US8747894B2 (en) * 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
AU2015235977B2 (en) 2014-03-26 2019-02-14 Nanovis, LLC Anti-microbial device and method for its manufacture
PE20180026A1 (es) * 2015-01-27 2018-01-09 Florengale Llc Composicion topica curativa
US20170000747A1 (en) * 2015-06-05 2017-01-05 Glenn A. Goldstein Use of n-acetylcysteine amide in the treatment of acetaminophen overdose
EP4098282A1 (en) 2016-02-04 2022-12-07 Czap Research And Development, LLC Controlled-release and stratified cyclodextrin inclusion complex vehicles
CN110214004B (zh) 2017-01-24 2022-11-22 株式会社优盛制药 含有对乙酰氨基酚的注射剂组合物
US11389409B2 (en) * 2019-08-30 2022-07-19 Remedy Diagnostics LLC Transdermal device comprising acetaminophen prodrug
WO2021167974A1 (en) 2020-02-18 2021-08-26 Nevakar Inc. N-acetylcysteine compositions and methods
EP4238559A1 (en) * 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507350A (zh) * 2001-03-30 2004-06-23 ��������ҩ�ɷ����޹�˾ 治疗和预防药物中毒施用的n-乙酰半胱氨酸组合物及方法
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127645A (en) * 1976-05-21 1978-11-28 Life Savers, Inc. Effervescent tablet and method
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US5474757A (en) 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GB9305058D0 (en) * 1993-03-12 1993-04-28 Penn Pharm Ltd Pharmaceutical compositions
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
DE29707005U1 (de) 1997-04-18 1997-06-26 Klinge Pharma GmbH, 81673 München Stabilisiertes Arzneimittel enthaltend Cysteinylderivate
IT1311907B1 (it) * 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
WO2001068069A2 (en) 2000-03-15 2001-09-20 King's College London Pharmaceutical composition comprising paracetamol
WO2006069293A2 (en) * 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
JP5909750B2 (ja) * 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507350A (zh) * 2001-03-30 2004-06-23 ��������ҩ�ɷ����޹�˾ 治疗和预防药物中毒施用的n-乙酰半胱氨酸组合物及方法
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods

Also Published As

Publication number Publication date
JP2012533559A (ja) 2012-12-27
EP2453743A4 (en) 2012-12-26
WO2011008976A1 (en) 2011-01-20
CA2767833A1 (en) 2011-01-20
US20110014285A1 (en) 2011-01-20
EP2453743A1 (en) 2012-05-23
CN102573463A (zh) 2012-07-11
JP2015214576A (ja) 2015-12-03
CA2767833C (en) 2018-10-23
EP2453743B1 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
EP2453743B1 (en) N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
US8349359B2 (en) Liposomal formulation for oral administration of glutathione (reduced)
US20250000821A1 (en) Methods of using dipivefrin
KR20200029547A (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
KR20120047891A (ko) Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
IL182950A (en) Liposomal suspension for oral glutathione administration
WO2020180608A1 (en) Dipivefrin orally disintegrating tablet formulations
Shetty et al. Mechanisms and therapeutics of n-acetylcysteine: a recent update
JP5542309B2 (ja) 経口医薬組成物
JP5828609B2 (ja) 持続性解熱鎮痛消炎剤
KR102733397B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
US20160128954A1 (en) Methods of Treating Huntington's Disease Using Cysteamine Compositions
HK1173336A (en) N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen
JP4444721B2 (ja) 医薬組成物
WO2022208216A1 (en) An oral liquid formulation of metformin, teneligliptin, vitamin b12, atorvastatin and levothyroxine for diabetes
EP2965746B1 (en) An oral pharmaceutical composition comprising ibuprofen, ibuprofen sodium dihydrate, pseudoephedrine hydrochloride and chlorpheniramine maleate
WO2022204431A1 (en) Prevention and treatment of coronavirus infection
HK40036124A (en) Methods of using dipivefrin
KR20060094875A (ko) 코엔자임 큐텐을 유효 성분으로 함유하는 알코올성 장애의제거 및 완화제용 약학적 조성물과 그의 복용 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160622

RJ01 Rejection of invention patent application after publication